COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Epidemiology of Sepsis in Turkish ICUs.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03249246
Recruitment Status : Completed
First Posted : August 15, 2017
Last Update Posted : August 15, 2017
Turkish Society of Intensive Care, Sepsis Study Group
Information provided by (Responsible Party):
Nur Baykara, Turkish Intensive Care Society

Brief Summary:
The prevalence and mortality of sepsis in Turkey is not know at large. Turkish Society of Intensive Care Medicine, Sepsis Study Group conducted a multi-centre,point prevalence survey to determine the prevalence, causative micro-organisms and outcome of sepsis in Turkish ICUs.

Condition or disease Intervention/treatment
Sepsis Septic Shock Severe Sepsis Other: No intervention

Layout table for study information
Study Type : Observational
Actual Enrollment : 1499 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Epidemiology of Sepsis in Turkish ICUs :a National Point Prevalence Multi-centre Study.
Actual Study Start Date : January 27, 2016
Actual Primary Completion Date : January 28, 2016
Actual Study Completion Date : February 27, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Group/Cohort Intervention/treatment
Infection only
The patients have only infection
Other: No intervention
Infection + SIRS
Patients have infection plus systemic inflammatory response syndrome (SIRS)
Other: No intervention
Severe sepsis
Septic patients with newly developed organ dysfunctions
Other: No intervention
Septic shock
Sepsis plus sepsis related hypotension
Other: No intervention

Primary Outcome Measures :
  1. Prevalence of sepsis [ Time Frame: Up to 12 weeks. ]
    The prevalence of sepsis,Severe sepsis and septic shock on study day

Secondary Outcome Measures :
  1. Mortality rate of sepsis [ Time Frame: Mortality at 30 days ]
    Mortality rate of septic shock

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
All patients (>18 yr)present on the participating ICU or admitted to participating ICUs on study day

Inclusion Criteria:All patients present on or admitted to participating ICU on study day.

Exclusion Criteria:

  • Age<18 years
  • Patients who underwent cardiovascular surgery.
Publications of Results:
Other Publications:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Nur Baykara, Prof.Dr.Nur Baykara, Turkish Intensive Care Society Identifier: NCT03249246    
Other Study ID Numbers: TurkishICS
First Posted: August 15, 2017    Key Record Dates
Last Update Posted: August 15, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nur Baykara, Turkish Intensive Care Society:
Point prevalence
Additional relevant MeSH terms:
Layout table for MeSH terms
Systemic Inflammatory Response Syndrome
Pathologic Processes